NCT05579691已完成2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's Ataxia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Number of Participants with Treatment Emergent Adverse Events
研究概览
简要总结
To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).
详细描述
This is a double-blind, placebo-controlled, study evaluating two doses (25 mg and 50 mg) of CTI-1601.
This study will consist of at least 2 cohorts with 12 to 15 subjects participating in each cohort. Subjects will be dosed once daily (QD) for 14 days followed by dosing every other day (QOD) through Day 28.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a genetically confirmed diagnosis of FRDA manifested by homozygous GAA repeat expansions, with repeat sizing (if available) included on the diagnosis report.
- •Subject is biologically male or female, 18 years of age or older at screening.
- •Subject must have a mFARS score ≥ 20 and be able to traverse a distance of 25 feet with or without some assistive device (e.g., cane, walker, crutches, self-propelled wheelchair), and (a) be able to sit upright with thighs together and arms crossed without requiring support on more than two sides; (b) be able to transfer from bed to chair independently or with assistance if, in the opinion of the PI, the degree of physical disability does not result in undue risk to the subject while participating in the study; and (c) perform basic daily care, such as feeding themselves and personal hygiene, with minimal assistance.
- •Subject must weigh > 40.0 kg.
排除标准
- •Subjects are excluded from the study if any of the following exclusion criteria are met:
- •If the subject previously participated in a study of CTI-1601 (CLIN-1601-101 (NCT04176991) or CLIN-1601-102 (NCT04519567)) the subject may not enroll in this study if they experienced one or more of the following: (a) Serious Adverse Event (SAE) related to study drug; (b) Adverse Event (AE) defined as Grade 3 or higher according to the CTCAE version 5.0 (or higher), related to study drug; (c) some other event that supports the exclusion of the subject from participating in this study as determined by the Sponsor (i.e., an AE considered clinically significant by the Sponsor regardless of whether it met SAE criteria and regardless of CTCAE grade).
- •Subject who is confirmed as compound heterozygous (GAA repeat expansion on only one allele) for FRDA.
- •Subject used an investigational drug or device within 90 days prior to screening.
- •Subject requires use of amiodarone.
- •Subject used erythropoietin, etravirine, or gamma interferon 90 days prior to Screening.
- •Subject use of biotin supplementation that exceeds 30.0 mcg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to the first dose of study drug.
- •Subject uses more than 3.0 grams of acetaminophen daily.
- •Subject receives medication that requires SC injection in the abdomen or thigh.
- •Subject received a vaccination within 14 days of administration of the first dose of study drug or is scheduled to receive a vaccination within 14 days after administration of the last dose of study drug. As an exception, influenza and tetanus vaccines must be administered more than 72 hours prior to the first dose of study drug or 72 hours after the administration of the last dose of study drug.
- •Subject has a screening ECHO LVEF < 45%.
- •Male subject has a QTcF > 450 milliseconds or female subject has a QTcF > 470 milliseconds on an ECG.
- •Subject currently receiving or having received omaveloxolone within 30 days prior to Screening.
研究组 & 干预措施
CTI-160l
Experimental
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
干预措施: CTI-1601 (Biological)
Placebo
Placebo Comparator
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Number of Participants with Treatment Emergent Adverse Events
时间窗: Through study completion, an average of 93 days
Overall summary of Participants with Treatment Emergent Adverse Events
次要结局
- Changes from baseline in frataxin levels in buccal cells(At baseline and up to 58 days)
- Maximum observed plasma concentration (Cmax) of CTI-1601 after multiple doses(At baseline and up to 29 days)
- Time to maximum observed plasma concentration (tmax) of CTI-1601 after multiple doses(At baseline and up to 29 days)
- Changes from baseline in frataxin levels in skin punch cells(At baseline and up to 29 days)
- Time to last observed plasma concentration (tlast) of CTI-1601 after multiple doses(At baseline and up to 29 days)
- Area under the concentration time curve (AUC) of CTI-1601 from time 0 through the last measurable time point(At baseline and up to 29 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese SubjectsOverweightObesityNCT00444561AstraZeneca184
已完成
1 期
A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic DiseasesAtopic Healthy SubjectsAdult Subjects with Mild Allergic DiseasesNCT05061524Yuhan Corporation68
招募中
2 期
A Study of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia2024-518929-15-00Centessa Pharmaceuticals UK Limited96
已完成
2 期
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia SyndromeNCT05633407argenx53
已完成
2 期
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT01742208Lexicon Pharmaceuticals36